Biotechnology is expected to be a hot subsector this year as healthcare recovered further from
the COVID pandemic anything from startups to big pharma- from vaccines to new drugs for
diabetes, liver disease and obesity. This is shown on a weekly chart to show the long term trend
with XBI pivoting to bullish back in early November. I add long positions when I see a dip
on the 3-4hr chart. My targets are the fib retracement expectation at 116 confluent with
the first upper VWAP band line and then the 135-138 zone underneath the second upper line
shown in thin red on the chart. This ETF smooths out the volatility characteristic of some
of the smaller biotechnology firms making it safer albeit with lesser rewards expectations.
Positions in NVAX and MRNA are having a good start to the week and will reflect in a small
way in this ETF which has broad constituent stocks within its portfolio.